Table 1.
Seroconversion and seroprotection rates for anti-HBs antibodies in women initially seronegative before vaccinationa
| Antibody titer group and time point | HepB+HPV group |
HepB group |
||
|---|---|---|---|---|
| No. of women | Rate (% [95% CI]) | No. of women | Rate (% [95% CI]) | |
| Seroconversion (titer ≥3.3 mIU/ml) | ||||
| Prevaccination | 55 | 0.0 (0.0–6.5) | 64 | 0.0 (0.0–5.6) |
| Month 2 | 55 | 83.6 (71.2–92.2) | 64 | 84.4 (73.1–92.2) |
| Month 3 | 55 | 100 (93.5–100) | 64 | 98.4 (91.6–100) |
| Month 13 | 52 | 100 (93.2–100) | 63 | 100 (94.3–100) |
| Seroprotection (titer ≥10 mIU/ml) | ||||
| Prevaccination | 55 | 0.0 (0.0–6.5) | 64 | 0.0 (0.0–5.6) |
| Month 2 | 55 | 58.2 (44.1–71.3) | 64 | 70.3 (57.6–81.1) |
| Month 3 | 55 | 96.4 (87.5–99.6) | 64 | 96.9 (89.2– 99.6) |
| Month 13 | 52 | 100 (93.2–100) | 63 | 100 (94.3–100) |
a
Data are from women who were seronegative for anti-HBs and anti-HBc before vaccination. Data are shown for the ATP active-phase cohort for the prevaccination, month 2, and month 3 time points and for the ATP HepB fourth-dose cohort for the month 13 time point.